{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.684","upperLimit":"0.400","value":"-0.64"},{"groupId":"OG001","lowerLimit":"0.776","upperLimit":"2.573","value":"1.67"}]}],"title":"Absolute Tissue Fat Mass"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.031","upperLimit":"0.759","value":"-0.14"},{"groupId":"OG001","lowerLimit":"0.887","upperLimit":"2.437","value":"1.66"}]}],"title":"Percent Tissue Fat Mass"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Tissue fat mass was measured by dual energy X-ray absorptiometry (DXA) scan. Reported are change in in absolute tissue fat mass and change in percent tissue fat mass.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (RW Phase)"},{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug.\n\nPlacebo: Placebo matched to study drug","id":"OG001","title":"Placebo (RW Phase)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The analysis population was patients in the ITT-RW Population.","reportingStatus":"POSTED","timeFrame":"Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)","title":"Percent Change in Tissue Fat Mass During the RW Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percent Change"}